

Vanguard DA2Pi-CPV-Lepto Lyophilisat et solvant pour suspension injectable pour chiens

Authorised

- Canine distemper virus, strain N-CDV, Live
- Canine parvovirus, strain NL-35-D, Live
- Canine adenovirus 2, strain Manhattan, Live
- Canine parainfluenza virus, strain NL-CPI-5, Live

Product identification

Medicine name:

Vanguard DA2Pi-CPV-Lepto Lyophilisat et solvant pour suspension injectable pour chiens

Vanguard DA2Pi-CPV-Lepto Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension

Active substance:

Canine distemper virus, strain N-CDV, Live

Canine parvovirus, strain NL-35-D, Live

Canine adenovirus 2, strain Manhattan, Live

Canine parainfluenza virus, strain NL-CPI-5, Live

Target species:

Dog

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Canine distemper virus, strain N-CDV, Live

3.00 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parvovirus, strain NL-35-D, Live

7.00 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Canine adenovirus 2, strain Manhattan, Live

3.20 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Canine parainfluenza virus, strain NL-CPI-5, Live

6.00 log₁₀ 50% cell culture infectious dose / 1.00 millilitre(s)

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Withdrawal period by route of administration:

Subcutaneous use:

-

Dog

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI07AD04

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Luxembourg

Available in:

Luxembourg

Package description:

Vanguard DA2PI-CPV 1 dose Vial Lyophilisate and solvent for suspension for injection
Vanguard DA2PI-CPV 10 1 dose Vial Lyophilisate and solvent for suspension for injection
Vanguard DA2PI-CPV 100 1 dose Vial Lyophilisate and solvent for suspension for injection
Vanguard DA2PI-CPV 25 1 dose Vial Lyophilisate and solvent for suspension for injection

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

28/11/2005

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

Ministry Of Health And Social Security

Authorisation number:

V 087/93/11/0348

Date of authorisation status change:

21/06/2010

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.